Awaiting FDA Action: Novel NDAs And BLAs With User Fee Goal Dates In The Second Half 0f 2010
This article was originally published in Pharmaceutical Approvals Monthly
Sponsor & Product
You may also be interested in...
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Almost one-third fewer novel product applications are on FDA’s user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011